论文部分内容阅读
既往一些试图确定单个补体成分(C1q、C2、C3、C9)和CH50的水平与临床疾病活动性关系的研究所得结果各异,这些补体成分水平的改变不都是与SLE 的临床表现有关。为此,本文作者用双抗体夹心酶联免疫吸附试验对28例SLE 患者的128份血清标本中的末段补体复合物(TCC)—C5b-9的浓度进行了测定。并对其中11例SLE 患者在2年随访期内于疾病恶化和缓解期连续所取的77份血清标本作了动态观察测定,以了解TCC 浓度的改变与疾病活动性的关系。50名正常人血清作对照测
Previous studies attempting to determine the association between single complement components (CIq, C2, C3, C9) and CH50 levels and clinical disease activity have varied and these changes in complement components have not been associated with clinical manifestations of SLE. To do this, we used double-antibody sandwich enzyme-linked immunosorbent assay to determine the concentration of the final complement complement (TCC) -C5b-9 in 128 serum samples from 28 SLE patients. Totally 77 serum samples taken from 11 patients with SLE during the 2-year follow-up period during the course of disease progression and remission were dynamically observed to understand the relationship between the change of TCC concentration and disease activity. 50 normal serum for the control test